retatrutide is it available FDA Approval Status 2026: Everything We Know So Far Retatrutide – Peptide Proof

Glucagon in the Treatment of Pagets Disease of Bone

A new US deal between the Trump administration, Eli Lilly and Novo Nordisk will start GLP-1 medications on the TrumpRx platform at roughly US$350 per month, dropping to US$245 US over the next two years, but Canadian patients are unlikely to see direct benefit from the cross-border program

But the details of the deal including the policy underpinnings, economic implications, and public health outcomes are likely to determine whether the bold claims from the president become a reality

Application to patients with multiple sclerosis and systemic lupus erythematosus